• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

KIF23的全癌系统分析及基于KIF23的透明细胞肾细胞癌（ccRCC）预测模型

Systematic Pan-Cancer Analysis of KIF23 and a Prediction Model Based on KIF23 in Clear Cell Renal Cell Carcinoma (ccRCC).

作者信息

Bai Xiaojie, Cao Yuanfei, Yan Xin, Tuoheti Kurerban, Du Guowei, Chen Zhao, Wu Huahui, Guo Linfa, Liu Tongzu

机构信息

Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.

出版信息

Pharmgenomics Pers Med. 2021 Dec 30;14:1717-1729. doi: 10.2147/PGPM.S337695. eCollection 2021.

DOI:10.2147/PGPM.S337695
PMID:35002290
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8725058/
Abstract

PURPOSE

This study aims to carry out a pan-cancer analysis of kinesin family member 23 (KIF23) and construct a predictive model for the prognosis of clear cell renal cell carcinoma (ccRCC) patients.

METHODS

We evaluated the differential expression of KIF23 in pan-cancer by The Cancer Genome Atlas (TCGA) and Oncomine database. Then, the correlation between KIF23 with prognosis, clinical grade, stage, immune subtype, tumor mutation burden (TMB), microsatellite instability (MSI) and immune microenvironment was explored by TCGA, an integrated repository portal for tumor-immune system interactions (TISIDB) and cBioPortal. Subsequently, we screened out ferroptosis-related genes (FRGs) related to KIF23 and constructed a risk score model. Univariate Cox analysis was used to determine independent prognostic factors for ccRCC overall survival (OS), and a nomogram was established. Furthermore, gene set enrichment analysis (GSEA) was applied to study the biological functions and pathways of KIF23. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was carried out to evaluate the expression of KIF23.

RESULTS

KIF23 was highly expressed in most tumors. Further, KIF23 was strongly correlated with prognosis, clinical grade, stage, immune subtype, TMB, MSI and immune microenvironment in different tumors. We found that KIF23 was significantly associated with all aspects of ccRCC. Then, 8 FRGs were identified to construct a risk score model together with KIF23. And a prognostic nomogram prediction model of OS was established. After GSEA analysis, cell cycle, condensed chromosome and other physiological processes were screened out. Finally, qRT-PCR verified the high expression of KIF23 in ccRCC cell lines than normal kidney cell line.

CONCLUSION

KIF23 may act as a pivotal part in occurrence and progression of different tumors. In ccRCC, KIF23 can be a great prognostic biomarker, and the nomogram based on KIF23 may contribute to better treatment plans for ccRCC patients.

摘要

目的

本研究旨在对驱动蛋白家族成员23（KIF23）进行泛癌分析，并构建透明细胞肾细胞癌（ccRCC）患者预后的预测模型。

方法

我们通过癌症基因组图谱（TCGA）和Oncomine数据库评估KIF23在泛癌中的差异表达。然后，通过TCGA、肿瘤-免疫系统相互作用综合知识库门户（TISIDB）和cBioPortal探索KIF23与预后、临床分级、分期、免疫亚型、肿瘤突变负荷（TMB）、微卫星不稳定性（MSI）和免疫微环境之间的相关性。随后，我们筛选出与KIF23相关的铁死亡相关基因（FRGs）并构建风险评分模型。采用单因素Cox分析确定ccRCC总生存期（OS）的独立预后因素，并建立列线图。此外，应用基因集富集分析（GSEA）研究KIF23的生物学功能和通路。最后，进行定量实时聚合酶链反应（qRT-PCR）以评估KIF23的表达。

结果

KIF23在大多数肿瘤中高表达。此外，KIF23与不同肿瘤的预后、临床分级、分期、免疫亚型、TMB、MSI和免疫微环境密切相关。我们发现KIF23与ccRCC的各个方面均显著相关。然后，鉴定出8个FRGs与KIF23共同构建风险评分模型。并建立了OS的预后列线图预测模型。经过GSEA分析，筛选出细胞周期、浓缩染色体等生理过程。最后，qRT-PCR验证了KIF23在ccRCC细胞系中比正常肾细胞系高表达。

结论

KIF23可能在不同肿瘤的发生和发展中起关键作用。在ccRCC中，KIF23可作为一个重要的预后生物标志物，基于KIF23的列线图可能有助于为ccRCC患者制定更好的治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/278ef508ca94/PGPM-14-1717-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/52484d3c2a04/PGPM-14-1717-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/71b4881a62b4/PGPM-14-1717-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/b63a85171830/PGPM-14-1717-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/47b159ad0dac/PGPM-14-1717-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/25b3745524f1/PGPM-14-1717-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/55555ccd871c/PGPM-14-1717-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/20e7759fc140/PGPM-14-1717-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/7eb4b70f2196/PGPM-14-1717-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/c20b6245a056/PGPM-14-1717-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/e80553cf12fe/PGPM-14-1717-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/278ef508ca94/PGPM-14-1717-g0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/52484d3c2a04/PGPM-14-1717-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/71b4881a62b4/PGPM-14-1717-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/b63a85171830/PGPM-14-1717-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/47b159ad0dac/PGPM-14-1717-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/25b3745524f1/PGPM-14-1717-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/55555ccd871c/PGPM-14-1717-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/20e7759fc140/PGPM-14-1717-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/7eb4b70f2196/PGPM-14-1717-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/c20b6245a056/PGPM-14-1717-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/e80553cf12fe/PGPM-14-1717-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4466/8725058/278ef508ca94/PGPM-14-1717-g0011.jpg

相似文献

1
Systematic Pan-Cancer Analysis of KIF23 and a Prediction Model Based on KIF23 in Clear Cell Renal Cell Carcinoma (ccRCC).KIF23的全癌系统分析及基于KIF23的透明细胞肾细胞癌（ccRCC）预测模型
Pharmgenomics Pers Med. 2021 Dec 30;14:1717-1729. doi: 10.2147/PGPM.S337695. eCollection 2021.
2
Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.基于铁死亡相关基因特征预测透明细胞肾细胞癌患者的总生存期。
World J Surg Oncol. 2022 Apr 14;20(1):120. doi: 10.1186/s12957-022-02555-9.
3
Identification of KIF23 as a Prognostic Biomarker Associated With Progression of Clear Cell Renal Cell Carcinoma.鉴定KIF23作为与透明细胞肾细胞癌进展相关的预后生物标志物
Front Cell Dev Biol. 2022 Apr 11;10:839821. doi: 10.3389/fcell.2022.839821. eCollection 2022.
4
A Ferroptosis-Related Genes Model Allows for Prognosis and Treatment Stratification of Clear Cell Renal Cell Carcinoma: A Bioinformatics Analysis and Experimental Verification.一种铁死亡相关基因模型可用于透明细胞肾细胞癌的预后评估和治疗分层：一项生物信息学分析与实验验证
Front Oncol. 2022 Jan 27;12:815223. doi: 10.3389/fonc.2022.815223. eCollection 2022.
5
Construction of A Novel Ferroptosis-related Prognostic Risk Signature for Survival Prediction in Clear Cell Renal Cell Carcinoma Patients.构建新型铁死亡相关预后风险模型预测透明细胞肾细胞癌患者的生存情况。
Urol J. 2022 May 22;19(4):289-299. doi: 10.22037/uj.v19i.6999.
6
PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma.PSAT1 增强了基于分期的透明细胞肾细胞癌预后评估列线图模型的疗效。
BMC Cancer. 2024 Apr 13;24(1):463. doi: 10.1186/s12885-024-12183-z.
7
Analysis of Ferroptosis-Related LncRNAs Signatures Associated with Tumor Immune Infiltration and Experimental Validation in Clear Cell Renal Cell Carcinoma.与肿瘤免疫浸润相关的铁死亡相关长链非编码RNA特征分析及在肾透明细胞癌中的实验验证
Int J Gen Med. 2022 Mar 19;15:3215-3235. doi: 10.2147/IJGM.S354682. eCollection 2022.
8
A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma.对MYO6作为透明细胞肾细胞癌诊断、预后和免疫的有前景生物标志物的综合分析。
Transl Cancer Res. 2023 Aug 31;12(8):2071-2098. doi: 10.21037/tcr-23-227. Epub 2023 Aug 23.
9
Comprehensive analysis of new prognostic signature based on ferroptosis-related genes in clear cell renal cell carcinoma.基于铁死亡相关基因的透明细胞肾细胞癌新预后标志物的综合分析。
Aging (Albany NY). 2021 Aug 9;13(15):19789-19804. doi: 10.18632/aging.203390.
10
Identification of an independent immune-genes prognostic index for renal cell carcinoma.鉴定一个独立的免疫基因预后指标用于肾细胞癌。
BMC Cancer. 2021 Jun 29;21(1):746. doi: 10.1186/s12885-021-08367-6.

引用本文的文献

1
The midbody and midbody remnant: from cellular debris to signaling organelle with diagnostic and therapeutic potential.中间体及中间体残余物：从细胞碎片到具有诊断和治疗潜力的信号细胞器
Mol Biol Cell. 2025 Jul 1;36(7):re4. doi: 10.1091/mbc.E25-03-0120. Epub 2025 May 28.
2
The significance of ferroptosis in renal diseases and its therapeutic potential.铁死亡在肾脏疾病中的意义及其治疗潜力。
Heliyon. 2024 Aug 6;10(16):e35882. doi: 10.1016/j.heliyon.2024.e35882. eCollection 2024 Aug 30.
3
SIRT7 promotes the proliferation and migration of anaplastic thyroid cancer cells by regulating the desuccinylation of KIF23.

本文引用的文献

1
KIF23 promotes triple negative breast cancer through activating epithelial-mesenchymal transition.KIF23通过激活上皮-间质转化促进三阴性乳腺癌。
Gland Surg. 2021 Jun;10(6):1941-1950. doi: 10.21037/gs-21-19.
2
Mutation and Copy Number Alterations Analysis of KIF23 in Glioma.胶质瘤中KIF23的突变与拷贝数改变分析
Front Genet. 2021 May 3;12:646929. doi: 10.3389/fgene.2021.646929. eCollection 2021.
3
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
SIRT7 通过调节 KIF23 的去琥珀酰化来促进间变性甲状腺癌细胞的增殖和迁移。
BMC Cancer. 2024 Feb 15;24(1):210. doi: 10.1186/s12885-024-11965-9.
4
Pan-Cancer Analysis of Prognostic and Immune Infiltrates for the TMEM65, Especially for the Breast Cancer.TMEM65的预后和免疫浸润的泛癌分析，尤其是针对乳腺癌的分析。
Evid Based Complement Alternat Med. 2023 Apr 17;2023:9349494. doi: 10.1155/2023/9349494. eCollection 2023.
5
ESPL1 is Elevated in Hepatocellular Carcinoma and Predicts Prognosis.ESPL1在肝细胞癌中表达升高并可预测预后。
Int J Gen Med. 2022 Nov 28;15:8381-8398. doi: 10.2147/IJGM.S381188. eCollection 2022.
一线免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗肾细胞癌患者的生存与临床病理特征的关系：一项随机临床试验的荟萃分析。
Eur Urol Focus. 2022 Mar;8(2):514-521. doi: 10.1016/j.euf.2021.03.001. Epub 2021 Mar 11.
4
KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target.KIF23增强胰腺导管腺癌的细胞增殖，是一个有效的治疗靶点。
Ann Transl Med. 2020 Nov;8(21):1394. doi: 10.21037/atm-20-1970.
5
Prognostic significance of KIF23 expression in gastric cancer.KIF23表达在胃癌中的预后意义。
World J Gastrointest Oncol. 2020 Oct 15;12(10):1104-1118. doi: 10.4251/wjgo.v12.i10.1104.
6
Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.了解并解决基于腺病毒的卵巢癌病毒疗法成功的障碍。
Cancer Gene Ther. 2021 May;28(5):375-389. doi: 10.1038/s41417-020-00227-y. Epub 2020 Sep 19.
7
Visualizing and interpreting cancer genomics data via the Xena platform.通过Xena平台可视化和解读癌症基因组学数据。
Nat Biotechnol. 2020 Jun;38(6):675-678. doi: 10.1038/s41587-020-0546-8.
8
KIF23 activated Wnt/β-catenin signaling pathway through direct interaction with Amer1 in gastric cancer.KIF23 通过与 Amer1 的直接相互作用激活胃癌中的 Wnt/β-连环蛋白信号通路。
Aging (Albany NY). 2020 May 4;12(9):8372-8396. doi: 10.18632/aging.103146.
9
PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.PreMSIm：一个用于通过癌症中基因面板的表达谱预测微卫星不稳定性的R包。
Comput Struct Biotechnol J. 2020 Mar 19;18:668-675. doi: 10.1016/j.csbj.2020.03.007. eCollection 2020.
10
FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations.FerrDb：一个经过人工策管的资源，包含铁死亡调控物和铁死亡-疾病关联的标志物。
Database (Oxford). 2020 Jan 1;2020. doi: 10.1093/database/baaa021.